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Transcriptional Subtyping and 
CD8 Immunohistochemistry 
Identifies Patients With Stage II 
and III Colorectal Cancer With 
Poor Prognosis Who Benefit From 
Adjuvant Chemotherapy
INTRODUCTION
Colorectal cancer (CRC) has the third highest 
worldwide incidence.1 Although 75% of patients 
present with operable disease—mainly stages 
II and III—approximately 40% experience dis-
ease recurrence.2 Compared with surgery alone, 
adjuvant chemotherapy improves survival in 
only approximately 3% of patients with stage 
II disease, rising to 15% to 20% for those with 
stage III disease. Overall, there is a clear need 
for treatment-stratifying biomarkers in patients 
with stage II and III CRC.
Purpose Transcriptomic profiling of colorectal cancer (CRC) has led to the identification 
of four consensus molecular subtypes (CMS1 to 4) that have prognostic value in stage 
II and III disease. More recently, the Colorectal Cancer Intrinsic Subtypes (CRIS) clas-
sification system has helped to define the biology specific to the epithelial component 
of colorectal tumors; however, the clinical value of these classification systems in the 
prediction of response to standard-of-care adjuvant chemotherapy remains unknown.
Patients and Methods Using samples from four European sites, we assembled a novel 
cohort of patients with stage II and III CRC (n = 156 samples) and performed transcrip-
tomic profiling and targeted sequencing and generated a tissue microarray to enable 
integrated multiomics analyses. We also accessed data from two published cohorts of 
patients with stage II and III CRC: GSE39582 and GSE14333 (n = 479 and n = 185 sam-
ples, respectively).
Results The epithelial-rich CMS2 subtype of CRC benefitted significantly from treat-
ment with adjuvant chemotherapy in both stage II and III disease (P = .02 and P < .001, 
respectively), whereas the CMS3 subtype significantly benefitted in stage III only (P = .001). 
After CRIS substratification of CMS2, we observed that only the CRIS-C subtype sig-
nificantly benefitted from treatment with adjuvant chemotherapy in stage II and III dis-
ease (P = .0081 and P < .001, respectively), whereas the CRIS-D subtype significantly 
benefitted in stage III only (P = .0034). We also observed that CRIS-C patients with 
low levels of CD8+ tumor-infiltrating lymphocytes were most at risk for relapse in both 
stage II and III disease (log-rank P = .0031; hazard ratio, 12.18 [95% CI, 1.51 to 98.58]).
Conclusion Patient stratification using a combination of transcriptional subtyping and 
CD8 immunohistochemistry analyses is capable of identifying patients with poor prog-
nostic stage II and III disease who benefit from adjuvant standard-of-care chemotherapy. 
These findings are particularly relevant for patients with stage II disease, where the 
overall benefit of adjuvant chemotherapy is marginal.
JCO Precis Oncol. © 2018 by American Society of Clinical Oncology 
abstract
original report
Wendy L. Allen
Philip D. Dunne
Simon McDade
Enya Scanlon
Maurice Loughrey
Helen G. Coleman
Christopher McCann
Kristy McLaughlin
Zsuzsanna Nemeth
Najeeb Ashraf Syed
Puthen Veettil Jithesh
Ken Arthur
Richard Wilson
Vicky M. Coyle
Darragh McArt
Graeme I. Murray
Leslie Samuel
Paolo Nuciforo
Jose Jimenez
Guillem Argiles
Rodrigo Dienstmann
Josef Tabernero
Lucia Picariello
Luca Messerini
Stefania Nobili
Enrico Mini
Kieran Sheahan
Elizabeth Ryan
(continued)
Downloaded from ascopubs.org by 86.1.169.192 on June 11, 2020 from 086.001.169.192
Copyright © 2020 American Society of Clinical Oncology. All rights reserved. 
Significant advances have been made in the 
molecular stratification of CRC, leading to 
the identification of four consensus molecular 
subtypes (CMS1 to 4).3 CMS1 is enriched for 
microsatellite instability, is immune rich, and 
correlates with good prognosis, and CMS4 is 
stromal rich, with high levels of cancer-associated 
fibroblasts, and has a relatively poor prognosis. 
CMS3 is defined by the activation of multiple 
metabolic pathways, potentially as a result of its 
enrichment for KRAS mutations.4 The epithe-
lial-rich CMS2 is the largest group, accounting 
for approximately 40% of all tumors. Although 
the CMS classification provides valuable prog-
nostic information for early-stage CRC, its 
usefulness in selecting patients for adjuvant che-
motherapy is not clear.5-7 In addition, there are 
wide variations in clinical outcome within each 
CMS subtype, particularly CMS2; therefore, 
there is a clear need for refinement of this clas-
sification system.
To define the biology that specifically drives 
neoplastic epithelial cells, the colorectal cancer 
intrinsic subtypes (CRIS) classification system 
was developed.6 Using this approach, five can-
cer epithelium-specific subtypes (CRIS-A) were 
identified that, by focusing on tumor epithelium, 
can potentially identify aspects of neoplastic 
biology that would be masked by contributions 
from the tumor microenvironment when using 
the CMS approach.8,9 In this study, we explored 
the use of CMS and CRIS classifications to pre-
dict the response to standard-of-care adjuvant 
treatment.
PATIENTS AND METHODS
Development of a Multiomics Patient 
Cohort
Using a combination of transcriptome profiling, 
next-generation sequencing, and tissue microar-
ray generation, we developed a multiomics stage 
II and III CRC cohort. This taxonomy cohort 
was assembled from an initial cohort of 363 
patients with stage II and III disease from four 
European centers. Of these, 188 samples with 
> 50% tumor content passed quality control 
and were subjected to RNA and DNA analysis 
(Appendix).
Transcriptomics
High-quality transcriptomics data were obtained 
for 156 of the 188 samples (Almac Xcel array; 
Almac Diagnostics, Craigavon, United King-
dom). Data analysis was performed using the 
R Statistical Package (version 3.4.1; https://
www.r-project.org/foundation/). All CEL files 
were loaded into R and processed using the 
makecdfenv, affy, and limma packages. Resid-
ual technical batch effects were corrected 
using the Combat method (sva package), and 
data were deposited in the National Center for 
Biotechnology Information Gene Expression 
Omnibus repository (GSE103479). The clinical- 
pathologic details of this cohort are provided in 
Table 1.
Data Analysis
GSE3958210 and GSE1433311 CRC data sets 
were downloaded from the National Center for 
Biotechnology Information Gene Expression 
Omnibus repository and their respective CEL 
files uploaded into R. The clinical-pathologic 
details of these cohorts are provided in Table 1. 
Each data set was subjected to CMS and CRIS 
classification. Kaplan-Meier estimators and Cox 
proportional hazards regression analysis were 
assessed using the survival and survminer R 
packages. Correlations between CMS and CRIS 
subtypes were assessed using Caleydo plots 
(Caleydo 3.1.5 software; www.caleydo.org).
Tissue Microarray Construction
Tissue microarrays were generated with nine 
cores per tumor, incorporating three cores each 
from central tumor (CT), invasive front (IF) and 
tumor-adjacent stroma-rich (SR) regions. In 
addition, where available, three cores of adjacent 
normal colonic tissue were arrayed.
RESULTS
Molecular Subgroups
We initially assessed the proportion of CMS 
and CRIS subtypes3,6,12,13 (Data Supplement) 
that were present in our in-house multiomics 
taxonomy cohort (Table 1) and two other inde-
pendent publicly available cohorts, GSE3958210 
and GSE14333.11 These analyses revealed sim-
ilar proportions of each CMS (Mann-Whitney 
paired t test, P value range .625 to 1.0) and CRIS 
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subtype (Mann-Whitney paired t test, P value 
range .8125 to 1.0) compared with the published 
proportions of CMS and CRIS subtypes3,6 (Data 
Supplement).
Benefit From Adjuvant Fluorouracil-Based 
Chemotherapy in CMS
We used Kaplan-Meier analyses to determine 
the benefit from adjuvant fluorouracil (FU) - 
based chemotherapy in CMS1 to 4. In the taxon-
omy cohort, compared with patients who were 
treated with surgery alone, there were non-
significant trends, particularly in stage III for 
CMS2 patients who received chemotherapy, for 
improved overall survival (log-rank test P = .13 
and .056 for stage II and III, respectively; Data 
Supplement). Similar results were obtained in 
the larger GSE39582 cohort for stage II dis-
ease (log-rank test P = .071), whereas in stage 
III disease, this correlation reached significance 
(P = .001; Data Supplement). When we com-
bined the taxonomy and GSE39582 cohorts to 
increase statistical power, the benefit from adju-
vant chemotherapy for CMS2 was significant 
in both stage II disease (log-rank test P = .02; 
hazard ratio [HR], 0.21 [Wald test P = 3.52 × 10−2]; 
Fig 1A) and stage III disease (log-rank test P < 
.001; HR, 0.22 [Wald test P = 1.48 × 10−4]; 
Fig 1B). There was also significant benefit from 
adjuvant chemotherapy in the stage III CMS3 
subtype (log-rank test P = .001; HR, 0.16 [Wald 
test P = 2.95 × 10−3]; Data Supplement) and a 
trend for benefit from chemotherapy in the stage 
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Table 1. Clinical-Pathologic Details for the Taxonomy Data Set and GSE39582 Stage II and II Patient Public Data Set
Variable Taxonomy
GSE39582 
(stage II and III)
GSE14333 
(stage II and III)
Clinical site
Aberdeen 27.0 (17.3) — —
Barcelona 63.0 (40.4) — —
Florence 17.0 (10.9) — —
SVH Dublin 49.0 (31.4) — —
Mean age, years 69.37 (11.37; 37.0-94.0) 67.67 (12.97; 22.0-97.0) 65.70 (13.50; 26.0-92.0)
Sex (male/female) 88.0/68.0 (56.4/43.6) 269.0/212.0 (56.0/44.0) 98.0/87.0 (53.0/47.0)
TNM stage
IIA 70.0 (44.9) Stage II 271 (56.3) Stage II 94 (50.8)
IIB 8.0 (5.1) Stage III 210 (43.7) Stage III 91 (49.2)
IIC 6.0 (3.8)
IIIA 6.0 (3.9)
IIIB 47.0 (30.1)
IIIC 19.0 (12.2)
Treatment
Fluorouracil based* 66.0 (42.31) 149.0 (30.9) 85.0 (46.0)
Other — 61.0 (12.7) —
No treatment 87.0 (55.77) 269.0 (55.9) 100.0 (54.0)
Not recorded 3.0 (1.92) 2.0 (0.4) —
Mean lymph nodes examined 21.01 (13.84; 0-145) — —
Primary tumor localization
Left sided 86.0 (55.0) 282.0 (58.6) 77.0 (41.6)
Right sided 63.0 (40.0) 199.0 (41.4) 85.0 (46.0)
Not specified 7.0 (5.0) 0.0 23.0 (12.4)
Median follow-up, months 49.41 (39.67; 0.0-217.94) 61.26 (38.83; 0.0-201.0) 36.92 (26.05; 0.92-118.58)†
NOTE. Displayed are the numbers and percentages for each group. For age, mean lymph nodes examined, and for median follow-up (overall survival), the number, 
standard deviation (SD), and range are displayed.
*Fluorouracil, capecitabine, or tomudex with oxaliplatin, n = 38; fluorouracil or capecitabine, n = 27; fluorouracil with irinotecan, n = 1.
†For the GSE14333 data set, median follow-up measure was disease-free survival.
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II CMS3 subtype; however, this failed to reach 
significance (log-rank test P = .088; Data Sup-
plement). Of note, no significant benefit from 
adjuvant chemotherapy was observed in CMS1 
or CMS4, although a nonsignificant trend was 
observed in CMS4 stage III disease (log-rank 
test P = .089; Data Supplement).
These results suggest that the more epithelial 
CMS2 and CMS3 subgroups benefit from adju-
vant chemotherapy. In support of this, in a com-
bined analysis of CMS2 and CMS3, benefit from 
adjuvant chemotherapy was significant in both 
stage II disease (log-rank test P = .0042; HR, 
0.16 [Wald test P = .012]; Fig 1C) and stage III 
disease (log-rank test P < .001; HR, 0.20 [Wald 
test P = 1.14 × 10−6]; Fig 1D). In contrast, in a 
combined analysis of the CMS1 and CMS4 sub-
groups, no benefit from adjuvant chemotherapy 
was observed (Data Supplement).
When CMS2 subgroup results for stage II dis-
ease were adjusted for T stage (T4 v T3), age, 
and sex using Cox proportional hazards regres-
sion analysis, the significance of the benefit from 
chemotherapy was lost (HR, 0.31; Wald test 
P = .121; log likelihood ratio, 7.0 × 10−5; Fig 1E); 
however, in stage III disease, adjusting for 
T stage (T4 or N2 v T1 to T3/N1), age, and sex, 
the significance of benefit from chemotherapy 
in CMS2 was maintained (HR, 0.27; Wald test 
P = .007; log likelihood P = 3.25 × 10−5; Fig 1F). In 
Cox proportional hazards regression analyses of 
the combined CMS2 and CMS3 subgroups, the 
significance of benefit from chemotherapy was 
maintained in stage II disease (HR, 0.23; Wald 
test P = .049; log likelihood ratio, 2.72 × 10−5; Fig 
1G) and stage III disease (HR, 0.21; Wald test 
P < .001; log likelihood P = 3.19 × 10−7; Fig 1H).
Clinical Implications of Tumor-Intrinsic 
Stratification in CMS2
As previously reported,6 there are limited associ-
ations between CMS and CRIS classifications—
for example, CMS4 is distributed relatively 
evenly between the five CRIS subtypes (Data 
Supplement); however, some clear patterns were 
observed, with CMS2 almost exclusively dis-
tributed between CRIS-C, -D, and -E (Fig 2A). 
Subsequently, we investigated whether sub-
stratification of CMS2 into CRIS-C, -D, or -E 
could identify a more specific subset of patients 
with stage II and III disease who derive benefit 
from adjuvant chemotherapy. In the combined 
taxonomy/GSE39582 cohort, only the CRIS-C 
subgroup (the largest subgroup of CMS2: 50.2% 
(n = 110); Fig 2A) displayed significant benefit 
from chemotherapy in both stage II (log-rank 
test P = .0081; HR, 0.12 [Wald test P = .03]; Fig 
2B) and stage III disease (log-rank test P < .001; 
HR, 0.15 [Wald test P = 2.23 × 10−4]; Fig 2C) or 
combined stage II and III (log-rank test P = 3.5 
× 10−4; HR, 0.26 [Wald test P = 8.8 × 10−4]; Data 
Supplement). These results were confirmed in an 
additional independent cohort, GSE14333 (log-
rank test P = .02; HR, 0.12 [Wald test P = .05]; 
Data Supplement). In contrast, there was no sig-
nificant benefit from adjuvant chemotherapy in 
stage II CRIS-D patients (log-rank test P = .28) 
or in stage II and III CRIS-E patients (log-rank 
test P = .37 and P = .1, respectively); however, 
these analyses did reveal significant benefit from 
chemotherapy in stage III CRIS-D patients (log-
rank test P = .0034; HR, 0.21 [Wald test P = 7.74 
× 10−3]; Data Supplement). In the other 2 CRIS 
subgroups (CRIS-A and -B), no significant bene-
fit from adjuvant chemotherapy was observed in 
either stage II or III disease, although a nonsig-
nificant trend was observed in CRIS-A for stage 
III disease (P = .057; Data Supplement), which is 
consistent with this subgroup being enriched for 
CMS3, where a significant benefit was observed 
(Data Supplement). When CRIS-C results were 
adjusted for T stage, age, and sex using Cox pro-
portional hazards regression analyses, the bene-
fit from chemotherapy maintained significance 
in stage II disease (HR, 0.12; Wald test P = .045; 
log likelihood P = .0054; Fig 2D) and stage III 
disease (HR, 0.27; Wald test P = .02; log likeli-
hood P = 1.11 × 10−3; Fig 2E); furthermore, for 
combined stage II and III disease, adjusted HR 
was 0.20 (Wald test P < .001; log likelihood 
P = 7.5 × 10−6; Data Supplement). These results 
indicate that CRIS-C classification predicts ben-
efit from adjuvant chemotherapy in both patients 
with stage II and III disease independently of 
other clinicopathologic factors.
Immunohistochemical Assessment of CD8+ 
Tumor-Infiltrating Lymphocytes
Although benefit from adjuvant chemotherapy 
for CRIS-C patients is clear in stage II and III 
disease (Figs 2A-2D), approximately 70% of 
stage II CRIS-C patients survive with surgery 
alone (Fig 2B). Thus, we sought to define a rou-
tine method that could identify high-risk stage 
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Fig 1. (A and B) Kaplan-Meier plots of 5-year overall survival (OS) for consensus molecular subtype 2 (CMS2) patients who received adjuvant 
fluorouracil (FU) -based treatment (gold) and those who did not receive treatment (surgery alone, blue), in the (A) stage II combined (taxonomy 
and GSE39582) cohort and the (B) stage III combined (taxonomy and GSE39582) cohort. (C and D) Kaplan-Meier plots for 5-year OS for com-
bined CMS2 and CMS3 patients in the (C) stage II combined (taxonomy and GSE39582) cohort and the (D) stage III combined (taxonomy and 
GSE39582) cohort. Displayed is the log-rank test, along with the hazard ratio (HR) for the chemotherapy-treated group (continued on next page) 
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II CRIS-C patients who should be administered 
adjuvant FU-based chemotherapy. Initially, we 
examined sequencing data from the taxonomy 
and GSE39582 cohorts. As previously reported,6 
the CRIS-C subgroup is predominantly TP53 
mutant and KRAS wild type and almost exclu-
sively BRAF wild type (Data Supplement). In 
line with this genotype, we also found that the 
CRIS-C subgroup is associated with left-sided 
tumors (Fisher's exact test: CRIS-C against all 
others, P = 6.27 × 10−10; 95% CI, 2.26 to 5.48; 
odds ratio, 3.48); however, stratifying CRIS-C 
patients on the basis of either TP53 or KRAS 
mutational status did not identify CRIS-C 
patients who were at higher risk of relapse after 
surgery (data not shown).
Given that patients with stage II and III CRC 
with high levels of T-cell infiltration have bet-
ter prognoses,2 we next assessed whether T-cell 
infiltration could be used to distinguish between 
low- and high-risk CRIS-C patients. To account 
for potential intratumoral heterogeneity of puta-
tive biomarkers in specific tumor regions, TMAs 
were generated from the taxonomy cohort to 
incorporate three cores each from CT, IF, and 
tumor-adjacent SR regions. This unique design 
enables us to assess locoregional variations in 
biomarker expression. CD8 and CD3 levels 
were defined using immunohistochemistry, and 
patients were stratified into high and low groups 
using the median as cutoff (representative CD8 
and CD3 images; Figs 3A and 3B). Of interest, 
correlations between CD3 and CD8 scores were 
relatively low (Fig 3C). In combined analyses of 
stage II and III disease, CRIS-C patients whose 
tumors had high levels of CD8+ lymphocytes 
in the IF, SR, and CT regions had significantly 
better overall survival than did those with low 
levels (log-rank test P = .023, P = .032, and 
P = .011, respectively; Data Supplement). We 
further assessed CD8+ lymphocytes in histolog-
ically normal tissue adjacent to the tumor and 
found no difference in survival between high and 
low CD8 levels (log-rank test P = .72; Data Sup-
plement). Of note, no correlations were found 
between CD3+ lymphocyte levels and prognosis 
(IF log-rank test P = .55; SR log-rank test P = .75; 
CT log-rank test P = .8; normal log-rank test 
P = .82; Data Supplement).
For each patient, CD8 scores in each tumor 
subregion correlated closely with one another 
(P < .001; Data Supplement). We therefore com-
bined CD8 scores from each region where at least 
two of three cores were present per region—CT, 
IF, and SR—into an average score per patient. 
As expected on the basis of correlations for indi-
vidual regions (Data Supplement), applying this 
tumor average score to the combined stage II and 
III taxonomy cohort revealed that high levels of 
CD8+ lymphocytes identified CRIS-C patients 
with good prognosis (log-rank P = .0031; HR, 
12.18 [Wald test P = .0191]; Fig 4A). In contrast, 
average CD3 scores, which again did not cor-
relate closely with average CD8 scores (Fig 3C), 
were not prognostic (Fig 4B). Of importance, 
the tumor average CD8 score also robustly risk 
stratified stage II CRIS-C patients (log-rank 
P = .018; Fig 4C). Of note, CD8 mRNA expression 
was unable to distinguish good and poor progno-
sis patients (log-rank P = .83; Data Supplement), 
which indicates the need for immunohistochem-
istry in combination with transcriptomic profil-
ing for effective prognostication. Thus, CRIS-C 
patients with high levels of CD8+ lymphocytes 
have an excellent prognosis, which suggests 
that these patients do not require adjuvant che-
motherapy. In contrast, as less than one half of 
patients with stage II CRIS-C/CD8 low tumors 
survive with surgery alone (Fig 4C), and given 
the significant benefit of FU-based chemother-
apy in the CRIS-C subgroup (Fig 2), these data 
suggest that the CRIS-C/CD8 low subgroup 
should be treated with chemotherapy (Fig 4D).
DISCUSSION
More than a decade ago, the seminal paper 
from Galon et al14 demonstrated the impor-
tance of antitumor immunity in CRC by show-
ing the prognostic value of assessing immune 
infiltration. More recently, on the basis of gene 
expression patterns, it was proposed that CRC is 
composed of four distinct subtypes, called CMS.3 
6 ascopubs.org/journal/po JCO™ Precision Oncology
with 95% CIs and Wald test of significance. (E-H) Forest plots show the results from the adjusted Cox proportional hazards regression analysis for 
the (E) stage II CMS2 combined cohort, the (F) stage III CMS2 combined cohort, the (G) stage II CMS2 and CMS3 combined cohort, and the 
(H) stage III CMS2 and CMS3 combined cohort. Forest plots display the number of patients, HR for the chemotherapy-treated group with 95% 
CIs, and the Wald test of significance. The number of events and the log likelihood ratio is also displayed. For adjusted analyses, data are stratified 
by treatment and adjusted for T stage, sex, and age in stage II, and for age and sex in stage III. (*) Results defined as a significant hazard ratio in the 
Cox regression. AIC, Akaike's information criterion.
Fig 1. (Continued).
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This classification incorporates gene expression 
profiles from tumor, stroma, and immune cells. 
Recently, an alternative transcriptomics-based 
classification was proposed that focuses on 
gene expression exclusively within the tumor 
cell compartment. This CRIS classification 
approach maps closely to the tumor’s underlying 
mutations.6,15
In this study, we highlight the potential clinical 
utility of CMS for selecting patients with stage 
III CRC for adjuvant chemotherapy, with a 
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Fig 2. (A) Caleydo plots display mapping of patient samples from the consensus molecular subtype 2 to the Colorectal Cancer Intrinsic Subtypes 
(CRIS) in the combined (taxonomy and GSE39582) data sets. Plots were generated using Caleydo 3.1.5 software (www.caleydo.org). (B and C) 
Kaplan-Meier plots of 5-year overall survival (OS) for the (B) stage II CRIS-C combined cohort and the (C) stage III CRIS-C combined cohort. 
(D and E) Forest plots show results from the adjusted Cox proportional hazards regression analysis for (D) stage II and (E) stage III CRIS-C in the 
combined cohort. Forest plots display the number of patients, hazard ratio (HR) for the chemotherapy-treated group with 95% CIs, and the Wald 
test of significance. The number of events and the log likelihood ratio is also presented. (*) Results defined as a significant hazard ratio in the Cox 
regression. AIC, Akaike's information criterion.
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significant benefit from postsurgery chemother-
apy observed in the epithelial-rich CMS2 and 
CMS3 subgroups—both alone and combined—
but not in the more undifferentiated CMS1 or 
CMS4 subgroups.16,17 We show that additional 
stratification of CMS2 tumors into CRIS-C, 
CRIS-D, and CRIS-E identifies CRIS-C and 
CRIS-D as the subgroups of patients within 
CMS2 that derive a clear benefit from adjuvant 
chemotherapy in stage III disease.
In stage II CRC, use of chemotherapy after sur-
gery is still a matter of debate. Therapeutic ben-
efit from adjuvant chemotherapy is modest for 
this group as a whole, with an absolute improve-
ment in survival of approximately 3%.18-22 Cur-
rently, additional pathologic characteristics, such 
as obstruction, perforation, extramural venous 
invasion, and T stage (T4), are used to iden-
tify poor prognostic stage II disease and guide 
the decision of whether to start chemotherapy 
treatment.23 Additional methods of assessing the 
risk of recurrence in the adjuvant disease setting 
have been the focus of many studies in recent 
years,24-29 which has led to the development of 
the 12-gene Oncotype DX assay.30 This algo-
rithm has been extensively clinically tested31-33 
and demonstrated to identify patients with stage 
II disease who are at higher risk of recurrence 
and patients with stage III disease who are at 
lower risk of recurrence.34,35 Additional signa-
tures have been proposed, including the 18-gene 
prognostic classifier, known as ColoPrint,36 
and the 634-gene prognostic classifier, known 
as ColDX.27 The current study indicates that 
the transcriptionally definable CMS2/CRIS-C 
patient subgroup may be the cohort of patients 
within stage II disease that benefits from stan-
dard adjuvant FU-based chemotherapy. Of 
importance, this benefit was found to be inde-
pendent of T stage. Moreover, none of the other 
CRIS subgroups derived significant benefit from 
adjuvant chemotherapy in the stage II setting.
Subsequently, we found that low levels of 
tumoral/peritumoral CD8+ lymphoid cells could 
identify CRIS-C patients with stage II disease 
(and indeed stage III) who are most at risk for 
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Fig 4. (A-C) Kaplan- 
Meier plots of patients with 
(A) CD8-high versus  
CD8-low stage II and III 
disease in the Colorectal 
Cancer Intrinsic Subtype 
(CRIS) -C surgery-only,  
taxonomy cohort; (B) 
CD3-high versus CD3-low 
stage II and III disease in 
the CRIS-C surgery-only, 
taxonomy cohort; and (C) 
CD8-high versus CD8-
low stage II disease in the 
CRIS-C surgery-only, 
taxonomy cohort. Patients 
were split into high (blue) 
and low (gold) CD8 or CD3 
groups using the median as 
cutoff. Significance was as-
sessed using a log-rank test. 
(D) Diagram of a potential 
decision tree for treatment 
of patients with stage II dis-
ease in the CRIS-C cohort. 
CMS2, consensus molecular 
subtype 2; FU, fluorouracil; 
IHC, immunohistochemistry.
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relapse after surgery and who therefore should 
be administered adjuvant chemotherapy. These 
data correlate well with our previous study on 
the prognostic significance of immune-derived 
programmed death ligand 1 mRNA expression 
in CRC, in which we postulated that patients 
with low immune infiltrates would significantly 
benefit from adjuvant FU-based chemother-
apy after surgery.9,37 Meta-analysis of the IDEA 
(International Duration Evaluation of Adju-
vant Chemotherapy) collaboration examined 
whether a 3-month duration of oxaliplatin- 
containing adjuvant chemotherapy—FOLFOX4, 
modified FOLFOX6, or XELOX—is as effec-
tive as a 6-month schedule in patients with stage 
III CRC. This study found that the 3-month 
treatment was almost as effective as the 6-month 
treatment and reduced the risk of treatment- 
associated toxicity, thus concluding that a 
3-month treatment would be more beneficial for 
patients with low-risk (T1 to 3/N1 tumors) stage 
III disease.38 Our study suggests that levels of 
CD8+ lymphocytes could also be used to identify 
such low-risk patients, at least in the CRIS-C 
subgroup. Of note, CRIS-C is enriched for 
mutant TP53 and wild-type KRAS tumors,6 but 
neither of these established molecular markers 
provided additional information with regard to 
disease outcome within the CRIS-C subgroup.
Collectively, these results provide the first evi-
dence of the predictive value of the now well- 
established CMS and more recently described 
CRIS transcription-based classification systems. 
Our results also emphasize the utility of combin-
ing CMS and CRIS subtyping in a substratifica-
tion strategy to maximize clinical benefit from 
adjuvant FU-based chemotherapy in patients with 
stage II and III CRC. In addition, CRIS classifi-
cation, in combination with assessment of CD8 
tumor-infiltrating lymphocytes, would poten-
tially enable the prospective identification of the 
CRIS-C/CD8-low stage II patients who signifi-
cantly benefit from adjuvant FU-based chemo-
therapy. However, we recognize that there are a 
number of limitations in the current study, which 
was conducted on a relatively small number of 
retrospective samples that were collected out-
side of clinical trials, and we realize that this 
hypothesis-generating study now requires vali-
dation in either larger patient cohorts or strati-
fied trial cohorts enriched for the CRIS-C patient 
subtype. Nonetheless, this study suggests that 
transcription-based classification systems, such as 
CMS and CRIS, have the potential to be devel-
oped into patient stratification tools and, when 
used alone or alongside other molecular pathol-
ogy approaches, such as immunohistochemistry, 
could enable the selection of patients with CRC 
who are most likely to benefit from adjuvant 
chemotherapy, while at the same time sparing 
nonresponders the potentially harmful treatment- 
related adverse events and sequelae of chemother-
apy. Of importance, the CRIS subtyping method 
uses gene expression from tumor epithelial cells 
only and is independent of stromal-derived 
signals; therefore, the CRIS subgroups can be 
detected irrespective of the profiling technology 
used or the tissue source.15 Such robustness and 
reproducibility are critical for clinical translation. 
In conclusion, this study suggests that patients 
with stage III CRIS-C and stage II CRIS- 
C/CD8-low disease would benefit from adjuvant 
FU-based chemotherapy. This now requires 
additional validation in larger patient cohorts.
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Development of a Multiomics Patient Cohort
The taxonomy cohort was assembled from an initial cohort of 363 patients with stage II and III disease from four European 
Centers (Vall d’Hebron Institute of Oncology, Barcelona, Spain; St Vincent’s University Hospital, Dublin, Ireland; Univer-
sity of Florence, Florence, Italy; and University of Aberdeen, Aberdeen, United Kingdom). This work was approved by the 
Medicine, Dentistry, and Biomedical Sciences School Ethics Committee (ref: 12/12v4).
Samples from 194 patients with 50% or more tumor content as assessed by hematoxylin and eosin staining were subjected to 
RNA extraction. Of these, 188 samples passed quality control (spectrophotometer A260/280: 1.68 to 2.08; two distinct peaks 
18S and 28S on a bioanalyzer).
Data Analysis
GSE39582 and GSE14333 data sets represent 585 fresh frozen and 290 fresh frozen surgically resected primary tumor 
samples, respectively. Both data sets contain all stages (I to IV) and treated and untreated samples with accompanying clinical 
follow-up. Within the GSE39582 and GSE14333 data sets, only patients with stage II and III disease were selected for addi-
tional analysis—479 samples from GSE39582 and 185 samples from GSE14333.
The CMSclassifier R package was downloaded from github (https://github.com/Sage-Bionetworks/crcsc), and the CRISclassi-
fier R package was downloaded from Isella et al6 and implemented using the Nearest Template Prediction method.
Sequencing
Suitable-quality DNA was obtained for tumor samples (n = 188; ×500 mean coverage) and matched normal tissues (n = 128; 
×100 mean coverage) that were then sequenced using a Roche/Nimblegen Seq-Cap-EZ panel (Roche, Mannheim, Germany) 
of 130 clinically relevant colorectal cancer genes. Sequencing data were made available as multiple libraries for each sample. 
Data for samples were preprocessed and aligned according to best practices (Broad Institute: https://gatkforums.broadinsti-
tute.org/gatk/discussion/3060/how-should-i-pre-process-data-from-multiplexed-sequencing-and-multi-library-designs) using 
Burrows-Wheeler Aligner for alignment and GATK 3.4 for realignment and recalibration. For tumor-only samples, a panel of 
normals was generated using available normal samples. Mutect 3.1 (Cibulskis K, et al: Nat Biotechnol 31:213-219, 2013) was 
used for variant calling, and a variant effect predictor was used for annotation of filtered VCF files.
CD3 and CD8 Immunohistochemistry and Scoring
CD3 was detected using the anti-CD3 antibody 2GV6 (Ventana Medical Systems, Tucson, AZ) on the BenchMark XT stain-
ing platform (Ventana). CD8 was detected using the anti-CD8 antibody C8/144B (Dako, Carpinteria, CA) using the Leica 
Bond Max staining platform (Leica Microsystems, Wetzlar, Germany). For CD8 evaluation, 74% of samples had triplicate 
cores for all three regions analyzed. An additional 11% of samples had two of their three cores available for analysis. For CD3 
analysis, 88.9% of samples had triplicate cores for all three regions analyzed. An additional 3.4% of samples had two of their 
three cores present for analysis. For each tumor core, CD3+ and CD8+ T-cell populations were scored using the open access 
image analysis software QuPath (https://qupath.github.io; Bankhead P, et al: Sci Rep 7:16878, 2017). Measurements of tissue 
area and positive cell counts for each core provided cell density measurements, which are expressed as the number of positive 
cells per square millimeter of tissue. Subsequent analysis took a mean of each triplicate core where applicable. High and low 
CD3/CD8 levels were calculated using the median level as cutoff.
Statistical Analyses
For Kaplan-Meier survival analysis and Cox proportional hazards regression analysis, significance was assessed using log-rank 
and Wald tests, respectively. In addition, we calculated the log likelihood ratio. In all cases, the survival end point measured 
was 5-year overall survival, unless otherwise stated. Cox proportional hazards regression analysis was used to assess overall 
survival at 5 years for adjuvant chemotherapy before and after adjustment for age, T stage, and sex (stage II and III) and age, 
sex, and stage (stage II and III combined). For correlation analysis, Pearson’s correlation coefficient was calculated with a two-
tailed test of significance. Statistical analyses were calculated using the paired Mann-Whitney U test and Fisher's exact test, 
both two tailed. All statistical analyses were carried out in R, and P values < .05 indicated statistical significance.
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